BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND MYC, c-Myc, 4609, ENSG00000136997 AND Clinical Outcome
29 results:

  • 1. Clinicopathological Characterization of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Woo HY; Chae SW; DO SI; Na K
    Anticancer Res; 2022 Nov; 42(11):5601-5608. PubMed ID: 36288864
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. TUG1/MAZ/FTH1 Axis Attenuates the Antiglioma Effect of Dihydroartemisinin by Inhibiting Ferroptosis.
    Gong H; Gao M; Lin Y; Liu J; Hu Z; Liu J
    Oxid Med Cell Longev; 2022; 2022():7843863. PubMed ID: 36164395
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
    Naderi A
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.
    Sugita Y; Masuoka J; Kameda K; Takahashi K; Kimura Y; Higaki K; Furuta T; Ohshima K
    Brain Tumor Pathol; 2020 Oct; 37(4):127-135. PubMed ID: 32627089
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
    Owonikoko TK; Niu H; Nackaerts K; Csoszi T; Ostoros G; Mark Z; Baik C; Joy AA; Chouaid C; Jaime JC; Kolek V; Majem M; Roubec J; Santos ES; Chiang AC; Speranza G; Belani CP; Chiappori A; Patel MR; Czebe K; Byers L; Bahamon B; Li C; Sheldon-Waniga E; Kong EF; Williams M; Badola S; Shin H; Bedford L; Ecsedy JA; Bryant M; Jones S; Simmons J; Leonard EJ; Ullmann CD; Spigel DR;
    J Thorac Oncol; 2020 Feb; 15(2):274-287. PubMed ID: 31655296
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/myc pathway.
    Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Medulloblastoma: Molecular Classification-Based Personal Therapeutics.
    Archer TC; Mahoney EL; Pomeroy SL
    Neurotherapeutics; 2017 Apr; 14(2):265-273. PubMed ID: 28386677
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
    Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
    Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. CD133
    Garg N; Bakhshinyan D; Venugopal C; Mahendram S; Rosa DA; Vijayakumar T; Manoranjan B; Hallett R; McFarlane N; Delaney KH; Kwiecien JM; Arpin CC; Lai PS; Gómez-Biagi RF; Ali AM; de Araujo ED; Ajani OA; Hassell JA; Gunning PT; Singh SK
    Oncogene; 2017 Feb; 36(5):606-617. PubMed ID: 27775079
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. High expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma.
    Meng D; Chen Y; Yun D; Zhao Y; Wang J; Xu T; Li X; Wang Y; Yuan L; Sun R; Song X; Huai C; Hu L; Yang S; Min T; Chen J; Chen H; Lu D
    Oncotarget; 2015 Mar; 6(7):4901-19. PubMed ID: 25669971
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.
    Fiaschetti G; Schroeder C; Castelletti D; Arcaro A; Westermann F; Baumgartner M; Shalaby T; Grotzer MA
    Acta Neuropathol Commun; 2014 Apr; 2():39. PubMed ID: 24708907
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A study of embryonic stem cell-related proteins in human astrocytomas: identification of Nanog as a predictor of survival.
    Elsir T; Edqvist PH; Carlson J; Ribom D; Bergqvist M; Ekman S; Popova SN; Alafuzoff I; Ponten F; Nistér M; Smits A
    Int J Cancer; 2014 Mar; 134(5):1123-31. PubMed ID: 24037901
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Components of the canonical and non-canonical Wnt pathways are not mis-expressed in pituitary tumors.
    Colli LM; Saggioro F; Serafini LN; Camargo RC; Machado HR; Moreira AC; Antonini SR; de Castro M
    PLoS One; 2013; 8(4):e62424. PubMed ID: 23638078
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
    Khuong-Quang DA; Buczkowicz P; Rakopoulos P; Liu XY; Fontebasso AM; Bouffet E; Bartels U; Albrecht S; Schwartzentruber J; Letourneau L; Bourgey M; Bourque G; Montpetit A; Bourret G; Lepage P; Fleming A; Lichter P; Kool M; von Deimling A; Sturm D; Korshunov A; Faury D; Jones DT; Majewski J; Pfister SM; Jabado N; Hawkins C
    Acta Neuropathol; 2012 Sep; 124(3):439-47. PubMed ID: 22661320
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Biological and clinical heterogeneity of mycN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Bone morphogenetic protein-7 is a myc target with prosurvival functions in childhood medulloblastoma.
    Fiaschetti G; Castelletti D; Zoller S; Schramm A; Schroeder C; Nagaishi M; Stearns D; Mittelbronn M; Eggert A; Westermann F; Ohgaki H; Shalaby T; Pruschy M; Arcaro A; Grotzer MA
    Oncogene; 2011 Jun; 30(25):2823-35. PubMed ID: 21317922
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.
    Cho YJ; Tsherniak A; Tamayo P; Santagata S; Ligon A; Greulich H; Berhoukim R; Amani V; Goumnerova L; Eberhart CG; Lau CC; Olson JM; Gilbertson RJ; Gajjar A; Delattre O; Kool M; Ligon K; Meyerson M; Mesirov JP; Pomeroy SL
    J Clin Oncol; 2011 Apr; 29(11):1424-30. PubMed ID: 21098324
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Polycomb genes expression as a predictor of poor clinical outcome in children with medulloblastoma.
    Zakrzewska M; Zakrzewski K; Grešner SM; Piaskowski S; Zalewska-Szewczyk B; Liberski PP
    Childs Nerv Syst; 2011 Jan; 27(1):79-86. PubMed ID: 20717685
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Pediatric brain tumors: genetics and clinical outcome.
    Faria C; Miguéns J; Antunes JL; Salgado D; Nunes S; Barroso C; Martins Mdo C; Nunes VM; Roque L
    J Neurosurg Pediatr; 2010 Mar; 5(3):263-70. PubMed ID: 20192643
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Medulloblastomas: a correlative study of MIB-1 proliferation index along with expression of c-myc, ERBB2, and anti-apoptotic proteins along with histological typing and clinical outcome.
    Das P; Puri T; Suri V; Sharma MC; Sharma BS; Sarkar C
    Childs Nerv Syst; 2009 Jul; 25(7):825-35. PubMed ID: 19444455
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.